title: A new serologic index for low-grade non-Hodgkin's lymphoma based on initial CA125 and LDH serum levels.
abstract: BACKGROUND
  Serum CA125 (sCA125) was recently reported to be of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma (NHL). This report aims to investigate the prognostic value of a new serologic index combining sCA125 and LDH serum levels.
  
  
  METHODS
  One hundred thirty-seven patients were studied, sixty-three with histologically proven low-grade NHL, and seventy-four with a high-grade subtype.
  
  
  RESULTS
  sCA125 and LDH levels were elevated in more than one third of patients. sCA125 was more frequently increased than LDH in low-grade NHL. In this group, complete remission (CR) was achieved in 87, 45, and 0% (P = <2 x 10(-6)) of patients with normal sCA125 and LDH serum levels (Low-risk group), one parameter increased (Intermediate-risk group), and increased sCA125 and LDH serum levels (high-risk group), respectively. The estimated five-year overall survival was 97%, 67% and 22% for low, intermediate, and high-risk groups, respectively. This combination was the only parameter predictive of RFS and OS in multivariate analysis (P < 0.0001).
  
  
  CONCLUSIONS
  In this study the combination of s-LDH and sCA125 levels (normal vs. abnormal) was found to be an important prognostic factor in low-grade lymphoma and may be used in the selection of appropriate therapeutic approaches for individual patients.
authors.affiliation: Department of Hematology/Oncology, H pital Bretonneau, Tours, France. l.Benboubker@bretonneau.chu-tours.fr
authors.forename: L
authors.initials: L
authors.lastname: Benboubker
authors.forename: C
authors.initials: C
authors.lastname: Valat
authors.forename: C
authors.initials: C
authors.lastname: Linassier
authors.forename: G
authors.initials: G
authors.lastname: Cartron
authors.forename: M
authors.initials: M
authors.lastname: Delain
authors.forename: M
authors.initials: M
authors.lastname: Bout
authors.forename: F
authors.initials: F
authors.lastname: Fetissof
authors.forename: T
authors.initials: T
authors.lastname: Lefranq
authors.forename: J P
authors.initials: JP
authors.lastname: Lamagnere
authors.forename: P
authors.initials: P
authors.lastname: Colombat
mesh_terms: D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D018394:CA-125 Antigen / Q000097:blood*; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000097:blood*; D015993:Life Tables; D008228:Lymphoma, Non-Hodgkin / Q000097:blood* / Q000401:mortality / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009363:Neoplasm Proteins / Q000097:blood*; D009367:Neoplasm Staging; D011379:Prognosis; D012074:Remission Induction; D012720:Severity of Illness Index; D016019:Survival Analysis; D016896:Treatment Outcome; D001613:beta 2-Microglobulin / Q000032:analysis
chemical_list: D014408:Biomarkers, Tumor; D018394:CA-125 Antigen; D009363:Neoplasm Proteins; D001613:beta 2-Microglobulin; D007770:L-Lactate Dehydrogenase